Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
|Articles|December 9, 2021
Florida Cancer Specialists & Research Institute Announces Senior Leadership Promotions & Appointments
Promotions and additions to the senior leadership team of Florida Cancer Specialists & Research Institute.
Advertisement
Fort Myers, Florida —
- Chris Chadwick has joined FCS as vice president of Service Delivery & Infrastructure
- Inga Gonzalez has been promoted to senior vice president of Practice Operations
- John Mills has been promoted to vice president of Pharmacy Services
- Marilyn Morales, EdS, MS, MBA, LBBP, CPT, has been promoted to senior vice president of Organizational Effectiveness and Learning
- Amy Pacey, MBA, SPHR, has joined FCS as senior vice president of People & Culture
- Jeffrey Rubin has been promoted to senior vice president of Practice Operations
FCS chief executive officer Nathan H. Walcker said, “These individuals bring a depth of diversity, talent, skill, and expertise that is valued and so vital to our ongoing success. Collectively, they will help to further enhance our national reputation for exceptional and compassionate patient.”
Advertisement
Related to this article
Patients with Sjögren disease diagnosed over a year after symptom onset had 2.3 times the odds of moderate or greater disease activity, a US survey found.
An estimated 44,052 sports eye injuries were treated in 2025 and 1262 pickleball eye injuries in 2024; 99% of lawnmower eye injuries were at home.
Pola-R-GemOx extends median overall survival to 19.5 months in transplant-ineligible R/R DLBCL, per POLARGO.
Teva's Weltruza, a once-monthly subcutaneous olanzapine injection, requires no loading doses, oral supplementation, or postinjection monitoring.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The FDA approves atezolizumab with a fluoropyrimidine and oxaliplatin as adjuvant therapy for stage III dMMR colon cancer based on the ATOMIC trial.
Washington, DC, clinicians shared how order sets, pharmacist-led dosing, and better handoffs can close iron deficiency gaps in heart failure care.
Advertisement
Advertisement
Trending on AJMC
1
FDA Approves IV, Subcutaneous Atezolizumab for dMMR Colon Cancer
2
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
3
Bumetanide Nasal Spray Targets Heart Failure Edema Before IV
4
Timing COVID-19 Protection With VYD2311: Michael Mina, MD, PhD
5